Home > Oncology > ASCO GU 2022 > Urothelial Carcinoma > Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma

Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma

Presented By
Dr Yohann Loriot, Institut Gustave Roussy, France
Conference
ASCO GU 2022
Trial
Phase 3, LEAP-011
Results from the phase 3 LEAP-011 trial showed that the combination of lenvatinib and pembrolizumab induced comparable anti-tumour activity compared with placebo plus pembrolizumab as first-line therapy in patients with advanced urothelial carcinoma who were ineligible for platinum-based chemotherapy. Pembrolizumab is an approved first-line therapy for patients with advanced urothelial carcinoma who are ineligible for platinum-based chemotherapy [1]. Lenvatinib, a multiple-receptor kinase inhibitor, has shown anti-tumour activity in several solid tumours [2]. When combined with pembrolizumab, lenvatinib showed promising early activity and manageable safety in previously treated patients with advanced urothelial carcinoma, regardless of PD-L1 status, in the phase 1b/2 KEYNOTE-146 trial [3]. The phase 3 LEAP-011 trial (NCT03898180) aimed to examine the combina...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on